COMPARATIVE COST ANALYSIS FOR TREATING GROWTH HORMONE DEFICIENCE IN BRAZIL- PEN VERSUS SYRINGES

Author(s)

Silva MA1, Mello IM1, Fernandes RA1, Almeida BG1, Manfrin DF2, Ferreira CN2
1ANOVA, Rio de Janeiro, Brazil, 2Pfizer, Inc., São Paulo, Brazil

OBJECTIVES: To compare costs of two delivery systems (pen vs. vials/syringes) of recombinant human growth hormone (rGH) in Brazilian GH deficient patients. METHODS: A budgetary impact model was developed to calculate total costs based on product waste (difference between prescribed dose and actual delivered dose, based on dosing increments for pens [Pfizer Gocquick 16UI and 36UI – P16 and P36, respectively] and a fixed-percent waste described in the literature for vials [Hormotrop 4UI and 12UI – V4 and V12, respectively]) and drug cost. Annual acquisition costs were calculated based upon total milligrams delivered, for pediatric and adult patients. Dose was 0,03mg/kg/day for children and 0,15mg/day for adults. It was considered both public and private payer perspectives. RESULTS: For children, calculated waste was 2.56% and 7.69% for P16 and P36, respectively; for adults, it was 0% for both versions. Waste for vials was fixed in 23% for all scenarios. From the public payer perspective, total cost per treatment-year for children was BRL26,256.96, BRL25,396.38, BRL33,702.73 and BRL32,683.92 for P16, P36, V4 and V12, respectively and waste cost was BRL2,019.77, BRL1,953.57, BRL7,751,63 and BRL7,517.30; for adults, total cost per treatment-year was BRL3,750.99, BRL3,628.05, BRL5,185,04 and BRL5,028.30 for P16, P36, V4 and V12, respectively and waste cost was BRL0.00, BRL0.00, BRL1,192.56 and BRL1,156,51. From the private payer perspective, total cost per treatment-year was, respectively, BRL32,027.03, BRL32,526.11, BRL43,164.19 and BRL41,858.67 for P16, P36, V4 and V12, and waste cost was BRL2,586.80, BRL2,502.01, BRL9,927.76 and BRL9,627.49 in children; for adults, total cost per treatment-year was BRL4,804.05, BRL4,646.59, BRL6,640.64 and BRL6,439.79 for P16, P36, V4 and V12, respectively and waste cost was BRL0.00, BRL0.00, BRL1,527.35 and BRL1,481.15. CONCLUSIONS: For pediatric and adult patients, rGH administration through pens was less costly, and had less waste than vials/syringes, from both public and private perspectives. P36 use was the best option in this analysis.

Conference/Value in Health Info

2014-05, ISPOR 2014, Palais des Congres de Montreal

Value in Health, Vol. 17, No. 3 (May 2014)

Code

PDB40

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×